{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:12Z","timestamp":1793406432628,"version":"4.5.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University","award":["IMSIU-DDRSP2601"],"award-info":[{"award-number":["IMSIU-DDRSP2601"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s15010-026-02817-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:49:13Z","timestamp":1778489353000},"page":"1803-1824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa"],"prefix":"10.1007","volume":"54","author":[{"given":"Hany M.","family":"Abdelmoneim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Mohammed","family":"Alhudhaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania H.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdi","family":"Bendif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-9529","authenticated-orcid":false,"given":"Tarek H.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2817_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1374466","author":"A Elfadadny","year":"2024","unstructured":"Elfadadny A, Ragab RF, AlHarbi M, Badshah F, Ib\u00e1\u00f1ez-Arancibia E, Farag A, et al. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front Microbiol Front Media SA. 2024. https:\/\/doi.org\/10.3389\/fmicb.2024.1374466.","journal-title":"Front Microbiol Front Media SA"},{"key":"2817_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71077","author":"A Nazir","year":"2025","unstructured":"Nazir A, Nazir A, Zuhair V, Aman S, Sadiq SUR, Hasan AH, et al. The global challenge of antimicrobial resistance: mechanisms, case studies, and mitigation approaches. Health Sci Rep. 2025. https:\/\/doi.org\/10.1002\/hsr2.71077.","journal-title":"Health Sci Rep"},{"key":"2817_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13040913","author":"M Hu","year":"2025","unstructured":"Hu M, Chua SL. Antibiotic-resistant Pseudomonas aeruginosa: current challenges and emerging alternative therapies. Microorganisms. 2025. https:\/\/doi.org\/10.3390\/microorganisms13040913.","journal-title":"Microorganisms"},{"key":"2817_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.37201\/req\/s01.13.2023","volume":"36","author":"M Pina-S\u00e1nchez","year":"2023","unstructured":"Pina-S\u00e1nchez M, Rua M, Del Pozo JL. Present and future of resistance in Pseudomonas aeruginosa: implications for treatment. Revista Espa\u00f1ola de Quimioterapia. 2023;36:54\u20138. https:\/\/doi.org\/10.37201\/req\/s01.13.2023.","journal-title":"Revista Espa\u00f1ola de Quimioterapia"},{"key":"2817_CR5","doi-asserted-by":"publisher","first-page":"e15724","DOI":"10.1016\/j.heliyon.2023.e15724","volume":"9","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu Y, Wang S, Zeng Z, Li Z, Din Y, et al. Antibiotic susceptibility pattern, risk factors, and prediction of carbapenem-resistant Pseudomonas aeruginosa in patients with nosocomial pneumonia. Heliyon. 2023;9:e15724. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15724.","journal-title":"Heliyon"},{"key":"2817_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1508941","author":"P Saha","year":"2025","unstructured":"Saha P, Kabir RB, Ahsan CR, Yasmin M. Multidrug resistance of Pseudomonas aeruginosa: do virulence properties impact on resistance patterns? Front Microbiol. 2025. https:\/\/doi.org\/10.3389\/fmicb.2025.1508941.","journal-title":"Front Microbiol"},{"key":"2817_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010199","author":"SJ Wood","year":"2023","unstructured":"Wood SJ, Kuzel TM, Shafikhani SH. Pseudomonas aeruginosa: infections, animal modeling, and therapeutics. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12010199.","journal-title":"Cells"},{"key":"2817_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.11.013","author":"Z Pang","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.11.013.","journal-title":"Biotechnol Adv"},{"key":"2817_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13020119","author":"C Yin","year":"2024","unstructured":"Yin C, Alam MZ, Fallon JT, Huang W. Advances in development of novel therapeutic strategies against multi-drug resistant Pseudomonas aeruginosa. Antibiotics. 2024. https:\/\/doi.org\/10.3390\/antibiotics13020119.","journal-title":"Antibiotics"},{"key":"2817_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2025.117907","author":"SB Santos","year":"2025","unstructured":"Santos SB, Costa MJ, Meneses L, Pires DP. Improved Pseudomonas aeruginosa detection through the development of an engineered reporter bacteriophage. Biosens Bioelectron. 2025. https:\/\/doi.org\/10.1016\/j.bios.2025.117907.","journal-title":"Biosens Bioelectron"},{"key":"2817_CR11","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001791","author":"S Ambreetha","year":"2024","unstructured":"Ambreetha S, Zincke D, Balachandar D, Mathee K. Genomic and metabolic versatility of Pseudomonas aeruginosa contributes to its inter-kingdom transmission and survival. J Med Microbiol. 2024. https:\/\/doi.org\/10.1099\/jmm.0.001791.","journal-title":"J Med Microbiol"},{"key":"2817_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.microb.2025.100645","author":"P Singh","year":"2026","unstructured":"Singh P, Arsi L. Pseudomonas aeruginosa biofilms: pathogenicity, clinical challenges and emerging therapeutic strategies. Microbe. 2026. https:\/\/doi.org\/10.1016\/j.microb.2025.100645.","journal-title":"Microbe"},{"key":"2817_CR13","unstructured":"WHO. WHO bacterial priority pathogens list. Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva; 2024."},{"key":"2817_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1088262","author":"W Huang","year":"2023","unstructured":"Huang W, Wei X, Xu G, Zhang X, Wang X. Carbapenem-resistant Pseudomonas aeruginosa infections in critically ill children: Prevalence, risk factors, and impact on outcome in a large tertiary pediatric hospital of China. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1088262.","journal-title":"Front Public Health"},{"key":"2817_CR15","doi-asserted-by":"publisher","first-page":"e18986","DOI":"10.7717\/peerj.18986","volume":"13","author":"MZ Salleh","year":"2025","unstructured":"Salleh MZ, Nik Zuraina NMN, Deris ZZ, Mohamed Z. Current trends in the epidemiology of multidrug-resistant and beta-lactamase-producing Pseudomonas aeruginosa in Asia and Africa: a systematic review and meta-analysis. PeerJ PeerJ Inc. 2025;13:e18986. https:\/\/doi.org\/10.7717\/peerj.18986.","journal-title":"PeerJ PeerJ Inc"},{"issue":"1","key":"2817_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2025.2580160","volume":"16","author":"MS Alharbi","year":"2025","unstructured":"Alharbi MS, Moursi SA, Alshammari A, Aboras R, Rakha E, Hossain A, et al. Multidrug-resistant Pseudomonas aeruginosa: pathogenesis, resistance mechanisms, and novel therapeutic strategies. Virulence. 2025;2580160. https:\/\/doi.org\/10.1080\/21505594.2025.2580160.","journal-title":"Virulence"},{"key":"2817_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01105-24","author":"A Candela","year":"2025","unstructured":"Candela A, Fern\u00e1ndez-Bill\u00f3n M, Aja-Macaya P, Gonz\u00e1lez-Pinto L, Fraile-Ribot PA, Viedma E, et al. Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem\/relebactam and MALDI-TOF MS. J Clin Microbiol Am Soc Microbiol. 2025. https:\/\/doi.org\/10.1128\/jcm.01105-24.","journal-title":"J Clin Microbiol Am Soc Microbiol"},{"key":"2817_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4065603","volume":"2016","author":"S Basak","year":"2016","unstructured":"Basak S, Singh P, Rajurkar M. Multidrug resistant and extensively drug resistant bacteria: a study. J Pathog. 2016;2016:1\u20135. https:\/\/doi.org\/10.1155\/2016\/4065603.","journal-title":"J Pathog"},{"key":"2817_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.infpip.2023.100296","author":"AF Yang","year":"2023","unstructured":"Yang AF, Huang V, Samaroo-Campbell J, Augenbraun M. Multi-drug resistant Pseudomonas aeruginosa: a 2019\u20132020 single center retrospective case control study. Infect Prev Pract. 2023. https:\/\/doi.org\/10.1016\/j.infpip.2023.100296.","journal-title":"Infect Prev Pract"},{"key":"2817_CR20","doi-asserted-by":"publisher","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","volume":"56","author":"E del Barrio-Tofi\u00f1o","year":"2020","unstructured":"del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Oliver A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update. Int J Antimicrob Agents. 2020;56:106196. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106196.","journal-title":"Int J Antimicrob Agents"},{"key":"2817_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.614058","author":"EJ Yoon","year":"2021","unstructured":"Yoon EJ, Jeong SH. Mobile Carbapenemase Genes in Pseudomonas aeruginosa. Front Microbiol Front Media S A. 2021. https:\/\/doi.org\/10.3389\/fmicb.2021.614058.","journal-title":"Front Microbiol Front Media S A"},{"key":"2817_CR22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/antibiotics12121699","volume":"12","author":"D Chotiprasitsakul","year":"2023","unstructured":"Chotiprasitsakul D, Trirattanapikul A, Namsiripongpun W, Chaihongsa N, Santanirand P. From Epidemiology of Community-Onset Bloodstream Infections to the Development of Empirical Antimicrobial Treatment-Decision Algorithm in a Region with High Burden of Antimicrobial Resistance. Antibiotics. 2023;12:1699. https:\/\/doi.org\/10.3390\/antibiotics12121699.","journal-title":"Antibiotics"},{"key":"2817_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13110975","author":"B Schwartz","year":"2024","unstructured":"Schwartz B, Klamer K, Zimmerman J, Kale-Pradhan PB, Bhargava A. Multidrug resistant Pseudomonas aeruginosa in clinical settings: a review of resistance mechanisms and treatment strategies. Pathogens. 2024. https:\/\/doi.org\/10.3390\/pathogens13110975.","journal-title":"Pathogens"},{"key":"2817_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90791-w","author":"R Eid","year":"2025","unstructured":"Eid R, Dabar G, Hanna LR, Saliba G, Riachy M, Choucair J, et al. Comparison of antimicrobial resistance in Pseudomonas aeruginosa from intensive care and non-intensive care units and its impact on treatment decisions. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-90791-w.","journal-title":"Sci Rep"},{"key":"2817_CR25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48204","author":"S Mendhe","year":"2023","unstructured":"Mendhe S, Badge A, Ugemuge S, Chandi D. Impact of Biofilms on Chronic Infections and Medical Challenges. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.48204.","journal-title":"Cureus"},{"key":"2817_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1736384","author":"X Yu","year":"2026","unstructured":"Yu X, Zhang Y, Yao Y, Cho WC, Shang A. Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. Front Microbiol. 2026. https:\/\/doi.org\/10.3389\/fmicb.2025.1736384.","journal-title":"Front Microbiol"},{"key":"2817_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2025.100224","volume":"8","author":"TC Dakal","year":"2026","unstructured":"Dakal TC, Dhakar R, Ahuja M, Gadi BR, Sharma NK. Mechanistic basis of multidrug resistance: current status, challenges, and potential solutions. Journal of Medicine, Surgery, and Public Health. 2026;8:100224. https:\/\/doi.org\/10.1016\/j.glmedi.2025.100224.","journal-title":"Journal of Medicine, Surgery, and Public Health"},{"key":"2817_CR28","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S156995","author":"I Ghai","year":"2018","unstructured":"Ghai I, Ghai S. Understanding antibiotic resistance via outer membrane permeability. Infect Drug Resist. 2018. https:\/\/doi.org\/10.2147\/IDR.S156995.","journal-title":"Infect Drug Resist"},{"key":"2817_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62010163","volume":"62","author":"A Kr\u016bmi\u0146a","year":"2026","unstructured":"Kr\u016bmi\u0146a A, Zelti\u0146a I, Simsone P, Eulitz E, Reinis A, V\u012bksna L. Mechanisms of Pseudomonas aeruginosa resilience against antibiotic treatment and outlooks of emerging treatment strategies. Medicina (B Aires). 2026;62:163. https:\/\/doi.org\/10.3390\/medicina62010163.","journal-title":"Medicina (B Aires)"},{"key":"2817_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics15010102","volume":"15","author":"RE Loredo-Puerta","year":"2026","unstructured":"Loredo-Puerta RE, Ni\u00f1o-Moreno P, Atriano-Briano RA, Mart\u00ednez-Alaniz KL, Baltazar-Benitez N, P\u00e9rez-Gonz\u00e1lez LF, et al. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa before the COVID-19 pandemic: resistance profiles and clonality in a tertiary-care hospital. Antibiotics. 2026;15:102. https:\/\/doi.org\/10.3390\/antibiotics15010102.","journal-title":"Antibiotics"},{"issue":"1","key":"2817_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-024-03249-w","volume":"24","author":"J Hemmati","year":"2024","unstructured":"Hemmati J, Nazari M, Abolhasani FS, Ahmadi A, Asghari B. In vitro investigation of relationship between quorum-sensing system genes, biofilm forming ability, and drug resistance in clinical isolates of Pseudomonas aeruginosa. BMC Microbiol. 2024;24. https:\/\/doi.org\/10.1186\/s12866-024-03249-w.","journal-title":"BMC Microbiol"},{"key":"2817_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01056-1","author":"S Qin","year":"2022","unstructured":"Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022. https:\/\/doi.org\/10.1038\/s41392-022-01056-1.","journal-title":"Signal Transduct Target Ther"},{"key":"2817_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1549044","author":"A Elbehiry","year":"2025","unstructured":"Elbehiry A, Marzouk E, Abalkhail A, Abdelsalam MH, Mostafa MEA, Alasiri M, et al. Detection of antimicrobial resistance via state-of-the-art technologies versus conventional methods. Front Microbiol. 2025. https:\/\/doi.org\/10.3389\/fmicb.2025.1549044.","journal-title":"Front Microbiol"},{"key":"2817_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1239269","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Huang S, Li F, Sun Y, Fu J, Xiao F, et al. Rapid detection of Pseudomonas aeruginosa by recombinase polymerase amplification combined with CRISPR-Cas12a biosensing system. Front Cell Infect Microbiol. 2023;13. https:\/\/doi.org\/10.3389\/fcimb.2023.1239269.","journal-title":"Front Cell Infect Microbiol"},{"key":"2817_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12111621","author":"F Giovagnorio","year":"2023","unstructured":"Giovagnorio F, De Vito A, Madeddu G, Parisi SG, Geremia N. Resistance in Pseudomonas aeruginosa: a narrative review of antibiogram interpretation and emerging treatments. Antibiotics Basel. 2023. https:\/\/doi.org\/10.3390\/antibiotics12111621.","journal-title":"Antibiotics Basel"},{"key":"2817_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111615","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals Basel. 2023. https:\/\/doi.org\/10.3390\/ph16111615.","journal-title":"Pharmaceuticals Basel"},{"key":"2817_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/biom15081182","author":"CT Ekwueme","year":"2025","unstructured":"Ekwueme CT, Anyiam IV, Ekwueme DC, Anumudu CK, Onyeaka H. Reconstructing the antibiotic pipeline: natural alternatives to antibacterial agents. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15081182.","journal-title":"Biomolecules"},{"key":"2817_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100081","volume":"2","author":"SK Ahmed","year":"2024","unstructured":"Ahmed SK, Hussein S, Qurbani K, Ibrahim RH, Fareeq A, Mahmood KA, et al. Antimicrobial resistance: impacts, challenges, and future prospects. Journal of Medicine, Surgery, and Public Health. 2024;2:100081. https:\/\/doi.org\/10.1016\/j.glmedi.2024.100081.","journal-title":"Journal of Medicine, Surgery, and Public Health"},{"key":"2817_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.imj.2023.05.003","author":"N Sathe","year":"2023","unstructured":"Sathe N, Beech P, Croft L, Suphioglu C, Kapat A, Athan E. Pseudomonas aeruginosa: infections and novel approaches to treatment \u201cknowing the enemy\u201d the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment. Infect Med. 2023. https:\/\/doi.org\/10.1016\/j.imj.2023.05.003.","journal-title":"Infect Med"},{"key":"2817_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/toxics13040303","author":"Y Pei","year":"2025","unstructured":"Pei Y, Hamar P, Pei DS. Deciphering multidrug-resistant Pseudomonas aeruginosa: mechanistic insights and environmental risks. Toxics. 2025. https:\/\/doi.org\/10.3390\/toxics13040303.","journal-title":"Toxics"},{"key":"2817_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041221","author":"C Verdial","year":"2023","unstructured":"Verdial C, Serrano I, Tavares L, Gil S, Oliveira M. Mechanisms of antibiotic and biocide resistance that contribute to Pseudomonas aeruginosa persistence in the hospital environment. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11041221.","journal-title":"Biomedicines"},{"key":"2817_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091230","author":"A Kothari","year":"2023","unstructured":"Kothari A, Kherdekar R, Mago V, Uniyal M, Mamgain G, Kalia RB, et al. Age of antibiotic resistance in MDR\/XDR clinical pathogen of Pseudomonas aeruginosa. Pharmaceuticals Basel. 2023. https:\/\/doi.org\/10.3390\/ph16091230.","journal-title":"Pharmaceuticals Basel"},{"key":"2817_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1599070","author":"T Ramatla","year":"2025","unstructured":"Ramatla T, Nkhebenyane J, Lekota KE, Thekisoe O, Monyama M, Achilonu CC, et al. Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis. Front Microbiol. 2025. https:\/\/doi.org\/10.3389\/fmicb.2025.1599070.","journal-title":"Front Microbiol"},{"key":"2817_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijid.2023.11.023","volume":"139","author":"Y Li","year":"2024","unstructured":"Li Y, Roberts JA, Walker MM, Aslan AT, Harris PNA, Sime FB. The global epidemiology of ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa: a systematic review and meta-analysis. Int J Infect Dis. 2024;139:78\u201385. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.023.","journal-title":"Int J Infect Dis"},{"key":"2817_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12121440","author":"S Jarzynka","year":"2023","unstructured":"Jarzynka S, Makarewicz O, Weiss D, Minkiewicz-Zochniak A, Iwa\u0144ska A, Skorupa W, et al. The impact of Pseudomonas aeruginosa infection in adult cystic fibrosis patients\u2014a single Polish centre study. Pathogens Basel. 2023. https:\/\/doi.org\/10.3390\/pathogens12121440.","journal-title":"Pathogens Basel"},{"key":"2817_CR46","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2024.23302","author":"A Rastegar-Kashkouli","year":"2024","unstructured":"Rastegar-Kashkouli A, Khaledi A, Moammer F, Ghenaatpisheh Sanani M, Heidari MM, Foroughi Eghbal A. Systematic review and meta-analysis on the prevalence and antibiotic susceptibility pattern in Pseudomonas aeruginosa isolated from cystic fibrosis patients. Eurasian J Med. 2024. https:\/\/doi.org\/10.5152\/eurasianjmed.2024.23302.","journal-title":"Eurasian J Med"},{"key":"2817_CR47","doi-asserted-by":"crossref","unstructured":"Malhotra S, Hayes D, Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. 2019.","DOI":"10.1128\/CMR.00138-18"},{"key":"2817_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2021","author":"S Van den Bossche","year":"2021","unstructured":"Van den Bossche S, De Broe E, Coenye T, Van Braeckel E, Crabb\u00e9 A. The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects. Eur Respir Rev. 2021. https:\/\/doi.org\/10.1183\/16000617.0055-2021.","journal-title":"Eur Respir Rev"},{"key":"2817_CR49","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","volume":"4","author":"J Reyes","year":"2023","unstructured":"Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 2023;4:e159-70. https:\/\/doi.org\/10.1016\/S2666-5247(22)00329-9.","journal-title":"Lancet Microbe"},{"key":"2817_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287762","author":"MT Arowolo","year":"2023","unstructured":"Arowolo MT, Orababa OQ, Olaitan MO, Osibeluwo BV, Essiet UU, Batholomew OH, et al. Prevalence of carbapenem resistance in Acinetobacter baumannii and Pseudomonas aeruginosa in sub-Saharan Africa: a systematic review and meta-analysis. PLoS One. 2023. https:\/\/doi.org\/10.1371\/journal.pone.0287762.","journal-title":"PLoS One"},{"key":"2817_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9461901","volume":"2020","author":"M Kindu","year":"2020","unstructured":"Kindu M, Derseh L, Gelaw B, Moges F. Carbapenemase-producing non-glucose-fermenting gram-negative bacilli in Africa, Pseudomonas aeruginosa and Acinetobacter baumannii: a systematic review and meta-analysis. Int J Microbiol. 2020;2020:1\u201318. https:\/\/doi.org\/10.1155\/2020\/9461901.","journal-title":"Int J Microbiol"},{"key":"2817_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad070","author":"A Sakurai","year":"2023","unstructured":"Sakurai A, Dinh AQ, Hanson BM, Shropshire WC, Rizvi SA, Rydell K, et al. Evolving landscape of carbapenem-resistant Pseudomonas aeruginosa at a single centre in the USA. JAC-Antimicrob Resist. 2023. https:\/\/doi.org\/10.1093\/jacamr\/dlad070.","journal-title":"JAC-Antimicrob Resist"},{"key":"2817_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062252","author":"M Bongiovanni","year":"2023","unstructured":"Bongiovanni M, Barda B. Pseudomonas aeruginosa bloodstream infections in SARS-CoV-2 infected patients: a systematic review. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12062252.","journal-title":"J Clin Med"},{"key":"2817_CR54","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s15010-024-02313-x","volume":"52","author":"E Sendra","year":"2024","unstructured":"Sendra E, Fern\u00e1ndez-Mu\u00f1oz A, Zamorano L, Oliver A, Horcajada JP, Juan C, et al. Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective. Infection. 2024;52:1235\u201368. https:\/\/doi.org\/10.1007\/s15010-024-02313-x.","journal-title":"Infection"},{"key":"2817_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321935","author":"R Itani","year":"2025","unstructured":"Itani R, Khojah HMJ, Mukattash TL, Shuhaiber P, Raychouni H, Dib C, et al. Difficult-to-treat resistant Pseudomonas aeruginosa infections in Lebanese hospitals: impact on mortality and the role of initial antibiotic therapy. PLoS One. 2025. https:\/\/doi.org\/10.1371\/journal.pone.0321935.","journal-title":"PLoS One"},{"key":"2817_CR56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jgar.2024.07.003","volume":"38","author":"J Zurita","year":"2024","unstructured":"Zurita J, Sevillano G, Sol\u00eds MB, Paz y Mi\u00f1o A, Alves BR, Changuan J, et al. Pseudomonas aeruginosa epidemic high-risk clones and their association with multidrug-resistant. J Glob Antimicrob Resist. 2024;38:332\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2024.07.003.","journal-title":"J Glob Antimicrob Resist"},{"key":"2817_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47070532","author":"B Libisch","year":"2025","unstructured":"Libisch B, Ozoaduche CL, Kereszt\u00e9ny T, Bus A, Van Limbergen T, Posta K, et al. Detection of the ST111 global high-risk Pseudomonas aeruginosa clone in a subway underpass. Curr Issues Mol Biol. 2025. https:\/\/doi.org\/10.3390\/cimb47070532.","journal-title":"Curr Issues Mol Biol"},{"key":"2817_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95950-7","author":"L Jin","year":"2025","unstructured":"Jin L, Ye H, Xu H, shahzadi A, Pan X, Lou D. Genomic epidemiology and characterization of difficult-to-treat resistant Pseudomonas aeruginosa isolates co-harboring blaOXA-50 and crpP causing bronchiectasis. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-95950-7.","journal-title":"Sci Rep"},{"key":"2817_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02020-25","volume":"16","author":"TL Luo","year":"2025","unstructured":"Luo TL, Jones BT, Dao H, Kondratiuk V, Kovalchuk V, Fomina N, et al. Recurring acquisition of carbapenemase genes and global emergence of Pseudomonas aeruginosa ST-1047, a lineage shaped by geopolitical conflicts. mBio. 2025;16:e0202025. https:\/\/doi.org\/10.1128\/mbio.02020-25.","journal-title":"mBio"},{"key":"2817_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241298826","author":"N Masoumi","year":"2024","unstructured":"Masoumi N, Keshavarzi F. The pattern of antibiotic resistance and distribution of the biofilm-producing Pseudomonas aeruginosa (PelD, PslB) isolated from infectious hospital departments. SAGE Open Med. 2024. https:\/\/doi.org\/10.1177\/20503121241298826.","journal-title":"SAGE Open Med"},{"key":"2817_CR61","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.69430","author":"V Monteiro-Neto","year":"2017","unstructured":"Monteiro-Neto V, Lima-Neto LG, Abreu AG, Monteiro CRAV. Microbiology of Ventilator-Associated Pneumonia Contemporary Topics of Pneumonia. InTech. 2017. https:\/\/doi.org\/10.5772\/intechopen.69430.","journal-title":"InTech"},{"key":"2817_CR62","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","volume":"48","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection. 2020;48:835\u201351. https:\/\/doi.org\/10.1007\/s15010-020-01520-6.","journal-title":"Infection"},{"key":"2817_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1648208","author":"R Vinaik","year":"2019","unstructured":"Vinaik R, Barayan D, Shahrokhi S, Jeschke MG. Management and prevention of drug-resistant infections in burn patients. Expert Rev Anti Infect Ther. 2019. https:\/\/doi.org\/10.1080\/14787210.2019.1648208.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2817_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113978","author":"D Salvatore","year":"2025","unstructured":"Salvatore D, Pepe A. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: a review of registry-based evidence. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14113978.","journal-title":"J Clin Med"},{"key":"2817_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/17534666251323194","author":"V Terlizzi","year":"2025","unstructured":"Terlizzi V, Lopes-Pacheco M. Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor. Ther Adv Respir Dis. 2025. https:\/\/doi.org\/10.1177\/17534666251323194.","journal-title":"Ther Adv Respir Dis"},{"key":"2817_CR66","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000001338","author":"SW Chun","year":"2024","unstructured":"Chun SW, Somers ME, Burgener EB. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind. Curr Opin Pediatr. 2024. https:\/\/doi.org\/10.1097\/MOP.0000000000001338.","journal-title":"Curr Opin Pediatr"},{"key":"2817_CR67","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202509-988ED","author":"L Perrem","year":"2025","unstructured":"Perrem L, McNally P. Real-world outcomes of elexacaftor\/tezacaftor\/ivacaftor in children with cystic fibrosis. Ann Am Thorac Soc. 2025. https:\/\/doi.org\/10.1513\/AnnalsATS.202509-988ED.","journal-title":"Ann Am Thorac Soc"},{"key":"2817_CR68","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001553","author":"JK Robertson","year":"2025","unstructured":"Robertson JK, Goldberg JB. The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota. Microbiology\u00a0(United Kingdom). 2025. https:\/\/doi.org\/10.1099\/mic.0.001553.","journal-title":"Microbiology\u00a0(United Kingdom)"},{"key":"2817_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/idr17040080","author":"CC Pescaru","year":"2025","unstructured":"Pescaru CC, Cri\u0219an AF, Mari\u021bescu A, C\u0103runta V, Marc M, Dumitrache-Rujinski \u0218, et al. Effects of CFTR modulators on Pseudomonas aeruginosa infections in Cystic Fibrosis. Infect Dis Rep. 2025. https:\/\/doi.org\/10.3390\/idr17040080.","journal-title":"Infect Dis Rep"},{"key":"2817_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2026.01.004","author":"V Terlizzi","year":"2026","unstructured":"Terlizzi V, Timitilli E, Fiumara MS, Dolce D, Campana S, Chiappini E. Detection of Pseudomonas aeruginosa in cystic fibrosis after initiation of CFTR modulators: a systematic review. Paediatr Respir Rev. 2026. https:\/\/doi.org\/10.1016\/j.prrv.2026.01.004.","journal-title":"Paediatr Respir Rev"},{"key":"2817_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123800","author":"M Garcia-Clemente","year":"2020","unstructured":"Garcia-Clemente M, de la Rosa D, M\u00e1iz L, Gir\u00f3n R, Blanco M, Olveira C, et al. Impact of Pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9123800.","journal-title":"J Clin Med"},{"key":"2817_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuab026","author":"AC Pelegrin","year":"2021","unstructured":"Pelegrin AC, Palmieri M, Mirande C, Oliver A, Moons P, Goossens H, et al. Pseudomonas aeruginosa: a clinical and genomics update. FEMS Microbiol Rev. 2021. https:\/\/doi.org\/10.1093\/femsre\/fuab026.","journal-title":"FEMS Microbiol Rev"},{"key":"2817_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.imj.2025.100168","volume":"4","author":"O Faruk","year":"2025","unstructured":"Faruk O, Jewel ZA, Bairagi S, Rasheduzzaman M, Bagchi H, Tuha ASM, et al. Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: the current status and future prospects. Infect Med. 2025;4:100168. https:\/\/doi.org\/10.1016\/j.imj.2025.100168.","journal-title":"Infect Med"},{"key":"2817_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2025.102103","author":"V Kundarapu","year":"2025","unstructured":"Kundarapu V, Shelke A, Priya P, Mishra S, Chauhan R, Dhingra S. Assessment of surgical site infections with antimicrobial resistance among cancer patients at a tertiary care hospital: a prospective study. Clin Epidemiol Glob Health. 2025. https:\/\/doi.org\/10.1016\/j.cegh.2025.102103.","journal-title":"Clin Epidemiol Glob Health"},{"key":"2817_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1039596","author":"H Pri\u00e9","year":"2022","unstructured":"Pri\u00e9 H, Meyssonnier V, Kerroumi Y, Heym B, Lidove O, Marmor S, et al. Pseudomonas aeruginosa prosthetic joint-infection outcomes: prospective, observational study on 43 patients. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.1039596.","journal-title":"Front Med"},{"key":"2817_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2020.102894","volume":"42","author":"JL Trevi\u00f1o Gonz\u00e1lez","year":"2021","unstructured":"Trevi\u00f1o Gonz\u00e1lez JL, Reyes Su\u00e1rez LL, Hern\u00e1ndez de Le\u00f3n JE. Malignant otitis externa: an updated review. Am J Otolaryngol. 2021;42:102894. https:\/\/doi.org\/10.1016\/j.amjoto.2020.102894.","journal-title":"Am J Otolaryngol"},{"key":"2817_CR77","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039462","author":"SC Yang","year":"2024","unstructured":"Yang SC, In Y, AlShammari SM, Kim MS. Rapid bone destruction caused by multidrug-resistant Pseudomonas aeruginosa septic arthritis: a case report. Medicine (United States). 2024. https:\/\/doi.org\/10.1097\/MD.0000000000039462.","journal-title":"Medicine (United States)"},{"key":"2817_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1270999","author":"E Jordana-Lluch","year":"2023","unstructured":"Jordana-Lluch E, Barcel\u00f3 IM, Escobar-Salom M, Est\u00e9vez MA, Zamorano L, G\u00f3mez-Zorrilla S, et al. The balance between antibiotic resistance and fitness\/virulence in Pseudomonas aeruginosa: an update on basic knowledge and fundamental research. Front Microbiol. 2023. https:\/\/doi.org\/10.3389\/fmicb.2023.1270999.","journal-title":"Front Microbiol"},{"key":"2817_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.926758","author":"C Liao","year":"2022","unstructured":"Liao C, Huang X, Wang Q, Yao D, Lu W. Virulence factors of Pseudomonas aeruginosa and antivirulence strategies to combat its drug resistance. Front Cell Infect Microbiol. 2022. https:\/\/doi.org\/10.3389\/fcimb.2022.926758.","journal-title":"Front Cell Infect Microbiol"},{"key":"2817_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2025.12911","volume":"30","author":"I Almami","year":"2025","unstructured":"Almami I. Genetic mutations enhance the production of Exotoxin A by Pseudomonas aeruginosa for use as a potential anticancer therapeutic agent. Exp Ther Med. 2025;30:1\u20138. https:\/\/doi.org\/10.3892\/etm.2025.12911.","journal-title":"Exp Ther Med"},{"key":"2817_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010195","author":"SJ Wood","year":"2023","unstructured":"Wood SJ, Goldufsky JW, Seu MY, Dorafshar AH, Shafikhani SH. Pseudomonas aeruginosa cytotoxins: mechanisms of cytotoxicity and impact on inflammatory responses. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12010195.","journal-title":"Cells"},{"key":"2817_CR82","unstructured":"Monych NK, Turner RJ. Multiple Compounds Secreted by Pseudomonas aeruginosa Increase the Tolerance of Staphylococcus aureus to the Antimicrobial Metals Copper and Silver. 2020."},{"key":"2817_CR83","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001596","author":"J Gorodetsky","year":"2025","unstructured":"Gorodetsky J, Monych N, Turner RJ, Haji-Ghassemi O, Booth SC. Role of AprA and pyocyanin from Pseudomonas aeruginosa on Staphylococcus aureus tolerance to silver. Microbiology (United Kingdom). Microbiology. 2025. https:\/\/doi.org\/10.1099\/mic.0.001596.","journal-title":"Microbiology"},{"key":"2817_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2021.126719","author":"G Horna","year":"2021","unstructured":"Horna G, Ruiz J. Type 3 secretion system of Pseudomonas aeruginosa. Microbiol Res. 2021. https:\/\/doi.org\/10.1016\/j.micres.2021.126719.","journal-title":"Microbiol Res"},{"key":"2817_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13120880","author":"KS Hardy","year":"2021","unstructured":"Hardy KS, Tessmer MH, Frank DW, Audia JP. Perspectives on the Pseudomonas aeruginosa Type III secretion system effector ExoU and its subversion of the host innate immune response to infection. Toxins Basel. 2021. https:\/\/doi.org\/10.3390\/toxins13120880.","journal-title":"Toxins Basel"},{"key":"2817_CR86","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.4049\/jimmunol.1102148","volume":"188","author":"Y Sun","year":"2012","unstructured":"Sun Y, Karmakar M, Taylor PR, Rietsch A, Pearlman E. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J Immunol. 2012;188:1884\u201395. https:\/\/doi.org\/10.4049\/jimmunol.1102148.","journal-title":"J Immunol"},{"key":"2817_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004934","volume":"11","author":"S Wood","year":"2015","unstructured":"Wood S, Goldufsky J, Shafikhani SH. Pseudomonas aeruginosa ExoT induces atypical anoikis apoptosis in target host cells by transforming Crk adaptor protein into a cytotoxin. PLoS Pathog. 2015;11:e1004934. https:\/\/doi.org\/10.1371\/journal.ppat.1004934.","journal-title":"PLoS Pathog"},{"key":"2817_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103127","volume":"9","author":"H Sato","year":"2014","unstructured":"Sato H, Frank DW. Intoxication of host cells by the T3SS phospholipase ExoU: PI (4,5) P2-associated, cytoskeletal collapse and late phase membrane blebbing. PLoS One. 2014;9:e103127. https:\/\/doi.org\/10.1371\/journal.pone.0103127.","journal-title":"PLoS One"},{"key":"2817_CR89","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/978-981-10-6141-7_16","volume-title":"Pathophysiological Aspects of Proteases","author":"ACM Galdino","year":"2017","unstructured":"Galdino ACM, Branquinha MH, Santos ALS, Viganor L. Pseudomonas aeruginosa and Its Arsenal of Proteases: Weapons to Battle the Host. In: Chakraborti S, Dhalla NS, editors. Pathophysiological Aspects of Proteases. Singapore: Springer Singapore; 2017. pp. 381\u201397. https:\/\/doi.org\/10.1007\/978-981-10-6141-7_16."},{"key":"2817_CR90","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.1926408","author":"CD Morin","year":"2021","unstructured":"Morin CD, D\u00e9ziel E, Gauthier J, Levesque RC, Lau GW. An organ system-based synopsis of Pseudomonas aeruginosa virulence. Virulence. 2021. https:\/\/doi.org\/10.1080\/21505594.2021.1926408.","journal-title":"Virulence"},{"key":"2817_CR91","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1128\/AEM.00637-11","volume":"77","author":"A Ghafoor","year":"2011","unstructured":"Ghafoor A, Hay ID, Rehm BHA. Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture. Appl Environ Microbiol. 2011;77:5238\u201346. https:\/\/doi.org\/10.1128\/AEM.00637-11.","journal-title":"Appl Environ Microbiol"},{"key":"2817_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11030300","author":"FF Tuon","year":"2022","unstructured":"Tuon FF, Dantas LR, Suss PH, Tasca Ribeiro VS. Pathogenesis of the Pseudomonas aeruginosa biofilm: A review. Pathogens Basel. 2022. https:\/\/doi.org\/10.3390\/pathogens11030300.","journal-title":"Pathogens Basel"},{"key":"2817_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1619626","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang D, Zhou D, Zheng S, Li S, Hou Q, et al. A comprehensive review of the pathogenic mechanisms of Pseudomonas aeruginosa: synergistic effects of virulence factors, quorum sensing, and biofilm formation. Front Microbiol Front Media SA. 2025. https:\/\/doi.org\/10.3389\/fmicb.2025.1619626.","journal-title":"Front Microbiol Front Media SA"},{"key":"2817_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2023.115389","author":"VC Kalia","year":"2023","unstructured":"Kalia VC, Patel SKS, Lee JK. Bacterial biofilm inhibitors: An overview. Ecotoxicol Environ Saf. 2023. https:\/\/doi.org\/10.1016\/j.ecoenv.2023.115389.","journal-title":"Ecotoxicol Environ Saf"},{"key":"2817_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061614","author":"S Sharma","year":"2023","unstructured":"Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial biofilm: A review on formation, infection, antibiotic resistance, control measures, and innovative treatment. Microorganisms Basel. 2023. https:\/\/doi.org\/10.3390\/microorganisms11061614.","journal-title":"Microorganisms Basel"},{"key":"2817_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-00005-6","author":"M Azimzadeh","year":"2025","unstructured":"Azimzadeh M, Greco G, Farmani A, Nourian A, Pourhajibagher M, Taherkhani A, et al. Biofilm inhibition of multidrug-resistant Pseudomonas aeruginosa using green-synthesized silver nanoparticles and colistin. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-00005-6.","journal-title":"Sci Rep"},{"key":"2817_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117008","volume":"281","author":"A Maiga","year":"2025","unstructured":"Maiga A, Ampomah-Wireko M, Li H, Fan Z, Lin Z, Zhen H, et al. Multidrug-resistant bacteria quorum-sensing inhibitors: a particular focus on Pseudomonas aeruginosa. Eur J Med Chem. 2025;281:117008. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117008.","journal-title":"Eur J Med Chem"},{"key":"2817_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13081838","author":"A Touati","year":"2025","unstructured":"Touati A, Ibrahim NA, Tighilt L, Idres T. Anti-QS strategies against Pseudomonas aeruginosa infections. Microorganisms Basel. 2025. https:\/\/doi.org\/10.3390\/microorganisms13081838.","journal-title":"Microorganisms Basel"},{"key":"2817_CR99","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1128\/JB.180.20.5443-5447.1998","volume":"180","author":"K Evans","year":"1998","unstructured":"Evans K, Passador L, Srikumar R, Tsang E, Nezezon J, Poole K. Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa. J Bacteriol. 1998;180:5443\u20137. https:\/\/doi.org\/10.1128\/JB.180.20.5443-5447.1998.","journal-title":"J Bacteriol"},{"key":"2817_CR100","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1128\/mmbr.67.4.593-656.2003","volume":"67","author":"H Nikaido","year":"2003","unstructured":"Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiology and Molecular Biology Reviews. 2003;67:593\u2013656. https:\/\/doi.org\/10.1128\/mmbr.67.4.593-656.2003.","journal-title":"Microbiology and Molecular Biology Reviews"},{"key":"2817_CR101","doi-asserted-by":"publisher","DOI":"10.1128\/mr.49.1.1-32.1985","author":"H Nikaidol","year":"1985","unstructured":"Nikaidol H, Vaara2 M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 1985. https:\/\/doi.org\/10.1128\/mr.49.1.1-32.1985.","journal-title":"Microbiol. Rev."},{"key":"2817_CR102","doi-asserted-by":"publisher","DOI":"10.1007\/BF00770245","author":"H Nikaido","year":"1993","unstructured":"Nikaido H. Transport across the bacterial outer membrane. J Bioenerg Biomembr. 1993. https:\/\/doi.org\/10.1007\/BF00770245.","journal-title":"J. Bioenerg. Biomembr."},{"key":"2817_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2008.11.005","author":"AH Delcour","year":"2009","unstructured":"Delcour AH. Outer membrane permeability and antibiotic resistance. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2009. https:\/\/doi.org\/10.1016\/j.bbapap.2008.11.005.","journal-title":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"},{"key":"2817_CR104","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1586\/eri.09.108","volume":"8","author":"AP Zavascki","year":"2010","unstructured":"Zavascki AP, Carvalhaes CG, Pic\u00e3o RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8:71\u201393. https:\/\/doi.org\/10.1586\/eri.09.108.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2817_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00660","author":"J Dreier","year":"2015","unstructured":"Dreier J, Ruggerone P. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front Microbiol Front Res Foundation. 2015. https:\/\/doi.org\/10.3389\/fmicb.2015.00660.","journal-title":"Front Microbiol Front Res Foundation"},{"key":"2817_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12081304","author":"A Avakh","year":"2023","unstructured":"Avakh A, Grant GD, Cheesman MJ, Kalkundri T, Hall S. The art of war with Pseudomonas aeruginosa: targeting Mex efflux pumps directly to strategically enhance antipseudomonal drug efficacy. Antibiotics. 2023. https:\/\/doi.org\/10.3390\/antibiotics12081304.","journal-title":"Antibiotics"},{"key":"2817_CR107","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.1c00055","author":"I Alav","year":"2021","unstructured":"Alav I, Kobylka J, Kuth MS, Pos KM, Picard M, Blair JMA, et al. Structure, assembly, and function of tripartite efflux and type 1 secretion systems in Gram-negative bacteria. Chem Rev. 2021. https:\/\/doi.org\/10.1021\/acs.chemrev.1c00055.","journal-title":"Chem Rev"},{"key":"2817_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01483","author":"M Alcalde-Rico","year":"2016","unstructured":"Alcalde-Rico M, Hernando-Amado S, Blanco P, Mart\u00ednez JL. Multidrug efflux pumps at the crossroad between antibiotic resistance and bacterial virulence. Front Microbiol Front Media SA. 2016. https:\/\/doi.org\/10.3389\/fmicb.2016.01483.","journal-title":"Front Microbiol Front Media SA"},{"key":"2817_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/life15010049","volume-title":"Biochemistry of Bacterial Biofilm: Insights into Antibiotic Resistance Mechanisms and Therapeutic Intervention","author":"K Azeem","year":"2025","unstructured":"Azeem K, Fatima S, Ali A, Ubaid A, Husain FM, Abid M. Biochemistry of Bacterial Biofilm: Insights into Antibiotic Resistance Mechanisms and Therapeutic Intervention. Multidisciplinary Digital Publishing Institute (MDPI); 2025. https:\/\/doi.org\/10.3390\/life15010049."},{"key":"2817_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1655335","author":"L Ren","year":"2025","unstructured":"Ren L, Yuan Y, Farea K, Feng X, He J, Liu Y, et al. The adaptability of Pseudomonas aeruginosa biofilm in oxygen-limited environments. Front Cell Infect Microbiol. 2025. https:\/\/doi.org\/10.3389\/fcimb.2025.1655335.","journal-title":"Front Cell Infect Microbiol"},{"key":"2817_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01866-5","author":"H Niu","year":"2024","unstructured":"Niu H, Gu J, Zhang Y. Bacterial persisters: molecular mechanisms and therapeutic development. Signal Transduction and Targeted Therapy. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01866-5.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2817_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00221-y","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xu H, Wang H, Wang P, Chen S. Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances. Molecular Biomedicine. 2024. https:\/\/doi.org\/10.1186\/s43556-024-00221-y.","journal-title":"Molecular Biomedicine"},{"key":"2817_CR113","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1128\/AAC.06380-11","volume":"56","author":"NS Ly","year":"2012","unstructured":"Ly NS, Yang J, Bulitta JB, Tsuji BT. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:3453\u20136. https:\/\/doi.org\/10.1128\/AAC.06380-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"2817_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12102051","author":"M Rossitto","year":"2024","unstructured":"Rossitto M, Fox V, Vrenna G, Tuccio Guarna Assanti V, Essa N, Lepanto MS, et al. The challenging life of mutators: how Pseudomonas aeruginosa survives between persistence and evolution in Cystic Fibrosis lung. Microorganisms. 2024. https:\/\/doi.org\/10.3390\/microorganisms12102051.","journal-title":"Microorganisms"},{"key":"2817_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027842","author":"AM Luj\u00e1n","year":"2011","unstructured":"Luj\u00e1n AM, Maci\u00e1 MD, Yang L, Molin S, Oliver A, Smania AM. Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. PLoS One. 2011. https:\/\/doi.org\/10.1371\/journal.pone.0027842.","journal-title":"PLoS One"},{"key":"2817_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.943346","author":"KM Hall","year":"2022","unstructured":"Hall KM, Pursell ZF, Morici LA. The role of the Pseudomonas aeruginosa hypermutator phenotype on the shift from acute to chronic virulence during respiratory infection. Front Cell Infect Microbiol Front Media S A. 2022. https:\/\/doi.org\/10.3389\/fcimb.2022.943346.","journal-title":"Front Cell Infect Microbiol Front Media S A"},{"key":"2817_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050526","author":"DW Zhao","year":"2025","unstructured":"Zhao DW, Lohans CT. Combatting Pseudomonas aeruginosa with \u03b2-Lactam antibiotics: a revived weapon? Antibiotics-Basel. 2025. https:\/\/doi.org\/10.3390\/antibiotics14050526.","journal-title":"Antibiotics-Basel"},{"key":"2817_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmic.2025.100134","author":"H Bawa","year":"2025","unstructured":"Bawa H, Mohammed K, Nuhu A, Shuaibu A, Akorede FR, Adesola O, et al. Carbapenemase-producing Pseudomonas aeruginosa isolated from patients exhibited multidrug resistance in Sokoto, Nigeria. Med Microecol. 2025. https:\/\/doi.org\/10.1016\/j.medmic.2025.100134.","journal-title":"Med Microecol"},{"key":"2817_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.12.026","author":"A Oliver","year":"2024","unstructured":"Oliver A, Rojo-Molinero E, Arca-Suarez J, Be\u015fli Y, Bogaerts P, Cant\u00f3n R, et al. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2023.12.026.","journal-title":"Clin Microbiol Infect"},{"key":"2817_CR120","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00694-24","author":"KA Glen","year":"2024","unstructured":"Glen KA, Lamont IL. Characterization of acquired \u03b2-lactamases in Pseudomonas aeruginosa and quantification of their contributions to resistance. Microbiol Spectr. 2024. https:\/\/doi.org\/10.1128\/spectrum.00694-24.","journal-title":"Microbiol Spectr"},{"key":"2817_CR121","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2048972","author":"FC Tenover","year":"2022","unstructured":"Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa \u2013an emerging challenge. Emerg Microbes Infect. 2022. https:\/\/doi.org\/10.1080\/22221751.2022.2048972.","journal-title":"Emerg Microbes Infect"},{"key":"2817_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060823","author":"F Baquero","year":"2025","unstructured":"Baquero F, Cant\u00f3n R, P\u00e9rez-Cobas AE, Coque TM, Levin B, Rodr\u00edguez-Beltr\u00e1n J. Antechodynamics and antechokinetics: dynamics and kinetics of antibiotic resistance biomolecules. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15060823.","journal-title":"Biomolecules"},{"key":"2817_CR123","doi-asserted-by":"publisher","unstructured":"Meletis G, Karastergiou E. Resistance mechanisms and therapeutic strategies for Pseudomonas aeruginosa infections. Ther. Adv. Infect. Dis. SAGE Publications Ltd; 2025. https:\/\/doi.org\/10.1177\/20499361251388382","DOI":"10.1177\/20499361251388382"},{"key":"2817_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10121638","author":"KA Glen","year":"2021","unstructured":"Glen KA, Lamont IL. \u03b2-lactam resistance in Pseudomonas aeruginosa: current status, future prospects. Pathogens Basel. 2021. https:\/\/doi.org\/10.3390\/pathogens10121638.","journal-title":"Pathogens Basel"},{"key":"2817_CR125","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/jac\/dkae203","volume":"79","author":"KA Glen","year":"2024","unstructured":"Glen KA, Lamont IL. Penicillin-binding protein 3 sequence variations reduce susceptibility of Pseudomonas aeruginosa to \u03b2-lactams but inhibit cell division. J Antimicrob Chemother. 2024;79:2170\u20138. https:\/\/doi.org\/10.1093\/jac\/dkae203.","journal-title":"J Antimicrob Chemother"},{"key":"2817_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/microbiolres16080183","author":"B Singh","year":"2025","unstructured":"Singh B, Dahiya M, Kumar V, Ayyagari A, Chaudhari DN, Ahire JJ. Biofilm and antimicrobial resistance: mechanisms, implications, and emerging solutions. Microbiol Res (Pavia). 2025. https:\/\/doi.org\/10.3390\/microbiolres16080183.","journal-title":"Microbiol. Res. (Pavia)"},{"key":"2817_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2023.100129","author":"M Fern\u00e1ndez-Bill\u00f3n","year":"2023","unstructured":"Fern\u00e1ndez-Bill\u00f3n M, Llamb\u00edas-Cabot AE, Jordana-Lluch E, Oliver A, Maci\u00e0 MD. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms. Biofilm Amst. 2023. https:\/\/doi.org\/10.1016\/j.bioflm.2023.100129.","journal-title":"Biofilm Amst"},{"key":"2817_CR128","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1586\/erp.10.49","volume":"10","author":"EB Hirsch","year":"2010","unstructured":"Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10:441\u201351. https:\/\/doi.org\/10.1586\/erp.10.49.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2817_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45766-0","author":"S Huang","year":"2023","unstructured":"Huang S, Wang X, Chen X, Liu X, Xu Q, Zhang L, et al. Rapid and sensitive detection of Pseudomonas aeruginosa by isothermal amplification combined with Cas12a-mediated detection. Sci Rep Nat Res. 2023. https:\/\/doi.org\/10.1038\/s41598-023-45766-0.","journal-title":"Sci Rep Nat Res"},{"key":"2817_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050509","author":"HI Al-Daghistani","year":"2025","unstructured":"Al-Daghistani HI, Abu-Niaaj LF, Zein S. Accurate diagnosis of Pseudomonas aeruginosa is critical to mitigating development of antibiotic resistance. Antibiotics Basel. 2025. https:\/\/doi.org\/10.3390\/antibiotics14050509.","journal-title":"Antibiotics Basel"},{"key":"2817_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040427","author":"I Gajic","year":"2022","unstructured":"Gajic I, Kabic J, Kekic D, Jovicevic M, Milenkovic M, Mitic Culafic D, et al. Antimicrobial susceptibility testing: a comprehensive review of currently used methods. Antibiotics Basel. 2022. https:\/\/doi.org\/10.3390\/antibiotics11040427.","journal-title":"Antibiotics Basel"},{"key":"2817_CR132","doi-asserted-by":"publisher","DOI":"10.1155\/jotm\/9694354","author":"Q Ghavami","year":"2025","unstructured":"Ghavami Q, Abd Ulhai Nasser H, Vaziri SS, Moghadam MT. A focused review on commercially available automated systems for antibiotic susceptibility testing. J Trop Med. 2025. https:\/\/doi.org\/10.1155\/jotm\/9694354.","journal-title":"J Trop Med"},{"key":"2817_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2025.100906","volume":"56","author":"N Sirad","year":"2025","unstructured":"Sirad N, Atalay MA, Sa\u011f\u0131ro\u011flu P. Evaluation of BD Phoenix and VITEK 2 for direct and routine antimicrobial susceptibility from positive blood culture bottles. Indian J Med Microbiol. 2025;56:100906. https:\/\/doi.org\/10.1016\/j.ijmmb.2025.100906.","journal-title":"Indian J Med Microbiol"},{"key":"2817_CR134","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","volume":"405","author":"N Macesic","year":"2025","unstructured":"Macesic N, Uhlemann A-C, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. The Lancet. 2025;405:257\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(24)02081-6.","journal-title":"The Lancet"},{"key":"2817_CR135","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1128\/JCM.00193-17","volume":"55","author":"VM Pierce","year":"2017","unstructured":"Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae. J Clin Microbiol. 2017;55:2321\u201333. https:\/\/doi.org\/10.1128\/JCM.00193-17.","journal-title":"J Clin Microbiol"},{"key":"2817_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031218","author":"M Reinicke","year":"2025","unstructured":"Reinicke M, Diezel C, Teimoori S, Haase B, Monecke S, Ehricht R, et al. Rapid simultaneous detection of the clinically relevant carbapenemase resistance genes blaKPC, blaOXA48, blaVIM and blaNDM with the newly developed ready-to-use qPCR CarbaScan LyoBead. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26031218.","journal-title":"Int J Mol Sci"},{"key":"2817_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2025.102298","volume":"41","author":"S Mallik","year":"2025","unstructured":"Mallik S, Dash S, Mishra S, Mohanty RB, Sahoo S, Patra A, et al. Threat of multidrug resistant bacteria: the role of genomic solutions and a call to action. Gene Reports. 2025;41:102298. https:\/\/doi.org\/10.1016\/j.genrep.2025.102298.","journal-title":"Gene Reports"},{"key":"2817_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.11.012","author":"MJ Ellington","year":"2017","unstructured":"Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect. 2017. https:\/\/doi.org\/10.1016\/j.cmi.2016.11.012.","journal-title":"Clin Microbiol Infect"},{"key":"2817_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106526","author":"P Yang","year":"2025","unstructured":"Yang P, Zeng J, Li L, Ma R, Peng J, Zhou W, et al. From Cas proteins to cutting-edge biosensors: a new era in clinical pathogen diagnostics. J Infect. 2025. https:\/\/doi.org\/10.1016\/j.jinf.2025.106526.","journal-title":"J Infect"},{"key":"2817_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/v12080845","author":"J Paczesny","year":"2020","unstructured":"Paczesny J, Richter \u0141, Ho\u0142yst R. Recent progress in the detection of bacteria using bacteriophages: a review. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12080845.","journal-title":"Viruses"},{"key":"2817_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.955286","author":"R Yin","year":"2022","unstructured":"Yin R, Cheng J, Wang J, Li P, Lin J. Treatment of Pseudomonas aeruginosa infectious biofilms: challenges and strategies. Front Microbiol. 2022. https:\/\/doi.org\/10.3389\/fmicb.2022.955286.","journal-title":"Front. Microbiol"},{"key":"2817_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107466","volume":"65","author":"Y Li","year":"2025","unstructured":"Li Y, Liu X, Yao H, Zhao X, Chi L, Jin CY, et al. The evolution of carbapenem-resistant Pseudomonas aeruginosa in the COVID-19 era: a global perspective and regional insights. Int J Antimicrob Agents. 2025;65:107466. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107466.","journal-title":"Int J Antimicrob Agents"},{"key":"2817_CR143","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000184","author":"M Saravanan","year":"2023","unstructured":"Saravanan M, Belete MA, Arockiaraj J. Carbapenem-resistant Pseudomonas aeruginosa in intensive care units increase mortality as an emerging global threat. Int J Surg. 2023. https:\/\/doi.org\/10.1097\/JS9.0000000000000184.","journal-title":"Int J Surg"},{"key":"2817_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050528","author":"I Karaiskos","year":"2025","unstructured":"Karaiskos I, Galani I, Daikos GL, Giamarellou H. Breaking through resistance: a comparative review of new beta-lactamase inhibitors (Avibactam, Vaborbactam, Relebactam) against multidrug-resistant superbugs. Antibiotics Basel. 2025. https:\/\/doi.org\/10.3390\/antibiotics14050528.","journal-title":"Antibiotics Basel"},{"key":"2817_CR145","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","volume":"20","author":"KM Papp-Wallace","year":"2019","unstructured":"Papp-Wallace KM. The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin Pharmacother. 2019;20:2169\u201384. https:\/\/doi.org\/10.1080\/14656566.2019.1660772.","journal-title":"Expert Opin Pharmacother"},{"key":"2817_CR146","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz368","author":"Z Li","year":"2019","unstructured":"Li Z, Cao Y, Yi L, Liu JH, Yang Q. Emergent polymyxin resistance: end of an era? Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz368.","journal-title":"Open Forum Infect Dis"},{"key":"2817_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1424765","author":"S Yang","year":"2024","unstructured":"Yang S, Wang H, Zhao D, Zhang S, Hu C. Polymyxins: recent advances and challenges. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1424765.","journal-title":"Front Pharmacol"},{"key":"2817_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2025.10350","author":"MK Abban","year":"2025","unstructured":"Abban MK, Ayerakwa EA, Isawumi A. Biofilm and surface-motility profiles under polymyxin B stress in multidrug-resistant KAPE pathogens isolated from Ghanaian hospital ICUs. Exp Biol Med Maywood. 2025. https:\/\/doi.org\/10.3389\/ebm.2025.10350.","journal-title":"Exp Biol Med Maywood"},{"key":"2817_CR149","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3635609","author":"SK Garg","year":"2017","unstructured":"Garg SK, Singh O, Juneja D, Tyagi N, Khurana AS, Qamra A, et al. Resurgence of Polymyxin B for MDR\/XDR Gram-negative infections: an overview of current evidence. Crit Care Res Pract. 2017. https:\/\/doi.org\/10.1155\/2017\/3635609.","journal-title":"Crit Care Res Pract"},{"key":"2817_CR150","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.2215\/CJN.08140718","volume":"14","author":"RF Eyler","year":"2019","unstructured":"Eyler RF, Shvets K. Clinical pharmacology of antibiotics. Clin J Am Soc Nephrol. 2019;14:1080\u201390. https:\/\/doi.org\/10.2215\/CJN.08140718.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2817_CR151","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S44377","author":"T Matsumoto","year":"2014","unstructured":"Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant gram-negative pathogens. Clin Pharmacol. 2014. https:\/\/doi.org\/10.2147\/CPAA.S44377.","journal-title":"Clin Pharmacol"},{"key":"2817_CR152","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5863\/1551-6776-27.3.214","volume":"27","author":"TA Imburgia","year":"2022","unstructured":"Imburgia TA, Kussin ML. A review of extended and continuous infusion beta-lactams in pediatric patients. J Pediatr Pharmacol Ther. 2022;27:214\u201327. https:\/\/doi.org\/10.5863\/1551-6776-27.3.214.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2817_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1533177","author":"Y Yu","year":"2025","unstructured":"Yu Y, He Z, Wang C. Monte Carlo simulation to optimize polymyxin B dosing regimens for the treatment of gram-negative bacteremia. Front Cell Infect Microbiol. 2025. https:\/\/doi.org\/10.3389\/fcimb.2025.1533177.","journal-title":"Front Cell Infect Microbiol"},{"key":"2817_CR154","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","volume":"25","author":"RK Shields","year":"2025","unstructured":"Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, et al. Effectiveness of ceftazidime\u2013avibactam versus ceftolozane\u2013tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025;25:574\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(24)00648-0.","journal-title":"Lancet Infect Dis"},{"key":"2817_CR155","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1093\/jac\/dkae313","volume":"79","author":"TP Lodise","year":"2024","unstructured":"Lodise TP, Obi EN, Watanabe AH, Yucel E, Min J, Nathanson BH. Comparative evaluation of early treatment with ceftolozane\/tazobactam versus ceftazidime\/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2024;79:2954\u201364. https:\/\/doi.org\/10.1093\/jac\/dkae313.","journal-title":"J Antimicrob Chemother"},{"key":"2817_CR156","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01697-22","author":"C Weber","year":"2022","unstructured":"Weber C, Schultze T, G\u00f6ttig S, Kessel J, Schr\u00f6der A, Tietgen M, et al. Antimicrobial activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against multidrug-resistant Pseudomonas aeruginosa recovered at a German university hospital. Microbiol Spectr. 2022. https:\/\/doi.org\/10.1128\/spectrum.01697-22.","journal-title":"Microbiol Spectr"},{"key":"2817_CR157","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9.","journal-title":"Lancet Infect Dis"},{"key":"2817_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238415","author":"A Z\u0142otowska","year":"2025","unstructured":"Z\u0142otowska A, Buzun WH, Pe\u0142ka K, Zalewska Z, Duszy\u0144ska W. The therapeutic potential of Cefiderocol in the treatment of multidrug-resistant Gram-Negative bacteria: A narrative review. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14238415.","journal-title":"J Clin Med"},{"key":"2817_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14020207","author":"N Parvin","year":"2025","unstructured":"Parvin N, Joo SW, Mandal TK. Nanomaterial-based strategies to combat antibiotic resistance: Mechanisms and applications. Antibiotics. 2025. https:\/\/doi.org\/10.3390\/antibiotics14020207.","journal-title":"Antibiotics"},{"key":"2817_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.temicr.2025.100052","volume":"2","author":"A Thakur","year":"2026","unstructured":"Thakur A, Ganesan R, Ray Dutta J. Nanomaterials against antimicrobial resistance and beyond: toward mitigating bacterial resuscitation. Total Environment Microbiology. 2026;2:100052. https:\/\/doi.org\/10.1016\/j.temicr.2025.100052.","journal-title":"Total Environment Microbiology"},{"key":"2817_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14111116","author":"G Bernab\u00e8","year":"2025","unstructured":"Bernab\u00e8 G, Marzaro G, Shalata MEM, Iosob D, Inglima V, Bellato M, et al. Repurposing MK-8245 as a quorum sensing inhibitor to suppress virulence and potentiate antibiotic activity in Pseudomonas aeruginosa. Antibiotics. 2025. https:\/\/doi.org\/10.3390\/antibiotics14111116.","journal-title":"Antibiotics"},{"key":"2817_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.microb.2025.100578","author":"MNI Bhuiyan","year":"2025","unstructured":"Bhuiyan MNI. Biofilm, resistance, and quorum sensing: the triple threat in bacterial pathogenesis. Microbe. 2025. https:\/\/doi.org\/10.1016\/j.microb.2025.100578.","journal-title":"Microbe"},{"key":"2817_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/biom16020197","volume":"16","author":"S Rosignoli","year":"2026","unstructured":"Rosignoli S, Lustrino E, Shevchuk O, Rinaldo S, Rubini E, Paiardini A, et al. Bioinformatics-driven, plant-based antibiotic research against quorum sensing and biofilm formation in Pseudomonas aeruginosa and Escherichia coli multiresistant microbes. Biomolecules. 2026;16:197. https:\/\/doi.org\/10.3390\/biom16020197.","journal-title":"Biomolecules"},{"key":"2817_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-025-04298-5","volume":"25","author":"W Song","year":"2025","unstructured":"Song W, Tian Z, Wang Y, Yin Y, Zhang H, Xu C, et al. Isoliquiritigenin targets las, rhl, and Pqs quorum sensing systems to mitigate the virulence and infection of Pseudomonas aeruginosa. BMC Microbiol. 2025;25:580. https:\/\/doi.org\/10.1186\/s12866-025-04298-5.","journal-title":"BMC Microbiol"},{"key":"2817_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35666","author":"F Eghbalpoor","year":"2024","unstructured":"Eghbalpoor F, Gorji M, Alavigeh MZ, Moghadam MT. Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35666.","journal-title":"Heliyon"},{"key":"2817_CR166","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115337","author":"LC Lin","year":"2025","unstructured":"Lin LC, Tsai YC, Lin NT. Phage\u2013antibiotic synergy enhances biofilm eradication and survival in a Zebrafish model of Pseudomonas aeruginosa infection. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26115337.","journal-title":"Int J Mol Sci"},{"key":"2817_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14101040","author":"S Zhang","year":"2025","unstructured":"Zhang S, Ahn J. Phage therapy as a novel alternative to antibiotics through adaptive evolution and fitness trade-offs. Antibiotics. 2025. https:\/\/doi.org\/10.3390\/antibiotics14101040.","journal-title":"Antibiotics"},{"key":"2817_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-02832-x","author":"DRA Sanya","year":"2023","unstructured":"Sanya DRA, On\u00e9sime D, Vizzarro G, Jacquier N. Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections. BMC Microbiol. 2023. https:\/\/doi.org\/10.1186\/s12866-023-02832-x.","journal-title":"BMC Microbiol"},{"key":"2817_CR169","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-025-03871-x","author":"P Mallari","year":"2025","unstructured":"Mallari P, Rostami LD, Alanko I, Howaili F, Ran M, Bansal KK, et al. The next frontier: unveiling novel approaches for combating multidrug-resistant bacteria. Pharm Res. 2025. https:\/\/doi.org\/10.1007\/s11095-025-03871-x.","journal-title":"Pharm Res"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02817-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:09:55Z","timestamp":1786702195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":169,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2817"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02817-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Statement\n                      .","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}